TABLE 1.
Overview of Four RAF Subgroups With Distinct Implications for Therapy That Are Defined on the Basis of Certain BRAF (or RAF1) Alterations Identified in Pancreatic Tumors via Genomic Profiling as well as the Presence or Absence of Confounding Drivers (eg, KRAS mutations) Which Might Otherwise Affect the Actionability of Therapies Targeting the MAPK Pathway
